Kelly CRISPR & Gene Editing Technology ETF (XDNA)

Assets	$2.93M
Expense Ratio	0.78%
PE Ratio	n/a
Shares Out	250,000
Dividend (ttm)	$0.01
Dividend Yield	0.08%
Ex-Dividend Date	Dec 22, 2022
Payout Ratio	n/a
1-Year Return	-10.55%

Volume	3,739
Open	11.55
Previous Close	11.76
Day's Range	11.55 - 11.77
52-Week Low	8.69
52-Week High	14.78
Beta	-1.99
Holdings	26
Inception Date	Jan 12, 2022

About XDNA

The Kelly CRISPR & Gene Editing Technology ETF (XDNA) is an exchange-traded fund that mostly invests in health care equity. The fund tracks a market-cap-weighted index of companies in developed markets that focus on the advancements in DNA modification technology. XDNA was launched on Jan 12, 2022 and is managed by Kelly.

• Asset Class: Equity
• Category: Health
• Region: Global
• Stock Exchange: NASDAQ
• Ticker Symbol: XDNA
• Issuer Website: Kelly
• Index Tracked: Strategic CRISPR & Gene Editing Technology

Top 10 Holdings

69.88% of assets

Name	Symbol	Weight
Beam Therapeutics Inc.	BEAM	10.41%
Thermo Fisher Scientific Inc.	TMO	10.39%
CRISPR Therapeutics AG	CRSP	10.09%
Intellia Therapeutics, Inc.	NTLA	8.53%
Poseida Therapeutics, Inc.	PSTX	7.45%
Prime Medicine, Inc.	PRME	5.15%
Editas Medicine, Inc.	EDIT	4.82%
Verve Therapeutics, Inc.	VERV	4.58%
Sangamo Therapeutics, Inc.	SGMO	4.45%
AbbVie Inc.	ABBV	3.99%

Dividends

Ex-Dividend	Amount	Pay Date
Dec 22, 2022	$0.00928	Dec 27, 2022